Entellus Medical Company Profile (NASDAQ:ENTL)

About Entellus Medical

Entellus Medical logoEntellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company's XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company's XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company's PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ENTL
  • CUSIP:
Key Metrics:
  • Previous Close: $13.92
  • 50 Day Moving Average: $17.31
  • 200 Day Moving Average: $18.77
  • 52-Week Range: $12.31 - $22.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.62
  • P/E Growth: -0.58
  • Market Cap: $295.34M
  • Outstanding Shares: 18,875,000
  • Beta: 0.26
Profitability:
  • Net Margins: -36.91%
  • Return on Equity: -53.20%
  • Return on Assets: -32.44%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 2.78%
  • Quick Ratio: 2.50%
Additional Links:
Companies Related to Entellus Medical:

Analyst Ratings

Consensus Ratings for Entellus Medical (NASDAQ:ENTL) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $22.80 (63.79% upside)

Analysts' Ratings History for Entellus Medical (NASDAQ:ENTL)
Show:
DateFirmActionRatingPrice TargetDetails
2/27/2017Canaccord GenuityReiterated RatingBuy$22.00View Rating Details
2/22/2017Bank of America CorpDowngradeBuy -> Underperform$16.00View Rating Details
2/22/2017BTIG ResearchDowngradeBuy -> NeutralView Rating Details
12/14/2016Piper Jaffray CompaniesReiterated RatingPositiveView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$25.00View Rating Details
11/4/2016Deutsche Bank AGReiterated RatingBuy$25.00 -> $26.00View Rating Details
9/23/2015William BlairReiterated RatingBuyView Rating Details
(Data available from 3/1/2015 forward)

Earnings

Earnings History for Entellus Medical (NASDAQ:ENTL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017        
2/21/2017Q4 2016($0.33)($0.39)$21.58 million$21.70 millionViewListenView Earnings Details
11/3/2016Q3($0.37)($0.50)$17.93 million$17.90 millionViewListenView Earnings Details
8/3/2016Q2($0.35)($0.27)$18.48 million$18.73 millionViewListenView Earnings Details
5/4/2016Q1($0.47)($0.37)$16.34 million$16.90 millionViewListenView Earnings Details
2/24/2016Q4($0.26)($0.27)$17.52 million$18.07 millionViewListenView Earnings Details
11/5/2015Q315($0.25)($0.32)$14.19 million$14.80 millionViewListenView Earnings Details
8/6/2015Q215($0.20)($0.15)$15.00 million$15.20 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.35)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Entellus Medical (NASDAQ:ENTL)
Current Year EPS Consensus Estimate: $-1.25 EPS
Next Year EPS Consensus Estimate: $-0.79 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.42)($0.42)($0.42)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.37)($0.37)($0.37)
Q4 20161($0.22)($0.22)($0.22)
Q1 20171($0.38)($0.38)($0.38)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.34)($0.34)($0.34)
Q4 20171($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Entellus Medical (NASDAQ:ENTL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Entellus Medical (NASDAQ:ENTL)
Insider Ownership Percentage: 9.10%
Institutional Ownership Percentage: 60.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2017Life Sciences Fu InternationalMajor ShareholderSell533,077$17.00$9,062,309.00View SEC Filing  
1/13/2017Brian E FarleyDirectorSell14,019$20.14$282,342.66View SEC Filing  
1/13/2017Karen E. PetersonVPSell10,000$20.13$201,300.00View SEC Filing  
1/10/2017Brian E FarleyDirectorSell9,842$19.11$188,080.62View SEC Filing  
1/10/2017Karen E. PetersonVPSell9,840$19.11$188,042.40View SEC Filing  
1/4/2017Brian E FarleyDirectorSell20,158$18.74$377,760.92View SEC Filing  
1/4/2017Karen E PetersonVPSell10,160$18.74$190,398.40View SEC Filing  
12/6/2016Brian E FarleyDirectorSell15,000$18.57$278,550.00View SEC Filing  
11/23/2016Brian E FarleyDirectorSell5,000$19.00$95,000.00View SEC Filing  
11/18/2016Brian E FarleyDirectorSell10,000$18.30$183,000.00View SEC Filing  
10/13/2016Margaret A. BoianoVPSell11,103$20.01$222,171.03View SEC Filing  
10/5/2016Brian E FarleyDirectorSell30,000$22.26$667,800.00View SEC Filing  
9/8/2016James D SurekVPSell10,000$18.71$187,100.00View SEC Filing  
9/2/2016Brian E FarleyDirectorSell11,078$18.62$206,272.36View SEC Filing  
9/1/2016Brian E FarleyDirectorSell17,006$19.33$328,725.98View SEC Filing  
9/1/2016Kevin L. MensinkVPSell8,000$18.39$147,120.00View SEC Filing  
8/1/2016Kevin L MensinkVPSell8,100$17.63$142,803.00View SEC Filing  
7/18/2016Timothy B. PetrickVPSell3,000$18.15$54,450.00View SEC Filing  
2/11/2016Karen E PetersonInsiderSell5,000$16.00$80,000.00View SEC Filing  
2/4/2016Karen E PetersonInsiderSell10,000$17.00$170,000.00View SEC Filing  
9/17/2015Brian E. FarleyChairmanSell5,484$22.00$120,648.00View SEC Filing  
9/15/2015Brian E. FarleyChairmanSell27,619$22.18$612,589.42View SEC Filing  
9/14/2015Brian E. FarleyChairmanSell21,187$22.15$469,292.05View SEC Filing  
9/2/2015James D SurekVPSell15,000$21.27$319,050.00View SEC Filing  
8/31/2015James D. SurekVPSell5,000$22.29$111,450.00View SEC Filing  
2/3/2015Robert S WhiteCOOBuy5,882$17.00$99,994.00View SEC Filing  
2/3/2015Shawn MccormickDirectorBuy2,941$17.00$49,997.00View SEC Filing  
2/3/2015Woodlands Health Venture EssexMajor ShareholderBuy352,941$17.00$5,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Entellus Medical (NASDAQ:ENTL)
DateHeadline
finance.yahoo.com logoENTELLUS MEDICAL INC Financials (NASDAQ:ENTL)
finance.yahoo.com - February 28 at 5:09 PM
News IconEntellus Medical Inc ENTL Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ENTL)
www.bioportfolio.com - February 28 at 8:23 AM
News IconEntellus Medical Inc (ENTL) is Downgraded by BofA/Merrill to " Underperform" (NASDAQ:ENTL)
prensariotiretail.com - February 24 at 10:49 PM
biz.yahoo.com logoQ4 2016 Entellus Medical Inc Earnings Release - After Market Close (NASDAQ:ENTL)
us.rd.yahoo.com - February 23 at 3:20 AM
biz.yahoo.com logoENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi (NASDAQ:ENTL)
us.rd.yahoo.com - February 23 at 3:19 AM
4-traders.com logoENTELLUS MEDICAL : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) (NASDAQ:ENTL)
www.4-traders.com - February 22 at 10:18 PM
biz.yahoo.com logoENTELLUS MEDICAL INC Files SEC form 10-K, Annual Report (NASDAQ:ENTL)
biz.yahoo.com - February 22 at 10:18 PM
marketexclusive.com logoAnalyst Downgrades – Entellus Medical (NASDAQ:ENTL) Stock Gets Downgraded By BTIG Research from Buy to Neutral (NASDAQ:ENTL)
marketexclusive.com - February 22 at 5:16 PM
zacks.com logoMoving Average Crossover Alert: Entellus Medical (ENTL) (NASDAQ:ENTL)
www.zacks.com - February 22 at 7:56 AM
finance.yahoo.com logoEntellus Medical Announces Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ENTL)
finance.yahoo.com - February 22 at 7:56 AM
sg.finance.yahoo.com logoEntellus reports 4Q loss (NASDAQ:ENTL)
sg.finance.yahoo.com - February 22 at 7:56 AM
4-traders.com logoENTELLUS MEDICAL INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) (NASDAQ:ENTL)
www.4-traders.com - February 1 at 5:34 PM
finance.yahoo.com logoEntellus Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 21, 2017 (NASDAQ:ENTL)
finance.yahoo.com - February 1 at 5:34 PM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bearish Manner : ENTL-US : January 27, 2017 (NASDAQ:ENTL)
www.capitalcube.com - January 27 at 6:39 PM
4-traders.com logoENTELLUS MEDICAL INC : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ENTL)
www.4-traders.com - January 26 at 6:20 PM
streetinsider.com logoEntellus Medical (ENTL) Commences $60M Offering of Common Stock (NASDAQ:ENTL)
www.streetinsider.com - January 26 at 6:20 PM
biz.yahoo.com logoENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial State (NASDAQ:ENTL)
us.rd.yahoo.com - January 25 at 11:20 PM
finance.yahoo.com logoEntellus Medical Announces Pricing of Public Offering of Common Stock (NASDAQ:ENTL)
finance.yahoo.com - January 25 at 11:20 PM
4-traders.com logoThe Insider Selling: Entellus Medical, Inc. (Entl) Vp Sells $188,042.40 in Stock (NASDAQ:ENTL)
www.4-traders.com - January 25 at 6:18 PM
nasdaq.com logoEntellus Medical Announces Proposed Public Offering of Common Stock (NASDAQ:ENTL)
www.nasdaq.com - January 25 at 6:18 PM
4-traders.com logoEntellus Medical : ENTL) VP Karen E. Peterson Sells 10,160 Shares of Stock (NASDAQ:ENTL)
www.4-traders.com - January 11 at 3:58 AM
marketexclusive.com logoAnalyst Activity – Canaccord Genuity Reiterates Buy on Entellus Medical (NASDAQ:ENTL) (NASDAQ:ENTL)
marketexclusive.com - January 6 at 3:51 AM
biz.yahoo.com logoENTELLUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princi (NASDAQ:ENTL)
biz.yahoo.com - January 5 at 5:49 PM
publicnow.com logoEntellus Medical Announces Management Promotions and Preliminary Revenue for Fourth Quarter and Full Year 2016 (NASDAQ:ENTL)
www.publicnow.com - January 5 at 5:49 PM
News IconEntellus Medical, Inc. ENTL Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:ENTL)
www.bioportfolio.com - December 31 at 3:28 AM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : December 26, 2016 (NASDAQ:ENTL)
www.capitalcube.com - December 26 at 11:19 AM
marketexclusive.com logoAnalyst Activity – Piper Jaffray Cos. Reiterates Positive on Entellus Medical (NASDAQ:ENTL) (NASDAQ:ENTL)
marketexclusive.com - December 15 at 5:34 PM
us.rd.yahoo.com logoNational Institute for Health and Care Excellence (NICE) Provides Positive Guidance for Use of the XprESS Multi-Sinus Dilation System for Treating Chronic Sinusitis (NASDAQ:ENTL)
us.rd.yahoo.com - December 13 at 10:40 PM
us.rd.yahoo.com logo9:30 am Entellus Medical announces that the National Institute for Health and Care Excellence Medical Technologies Advisory Committee provided positive guidance for use of the XprESS Multi-Sinus Dilation System for the treatment of chronic (NASDAQ:ENTL)
us.rd.yahoo.com - December 13 at 10:40 PM
nasdaq.com logoNational Institute for Health and Care Excellence (NICE) Provides Positive Guidance for Use of the (NASDAQ:ENTL)
www.nasdaq.com - December 13 at 11:31 AM
capitalcube.com logoEntellus Medical, Inc. – Value Analysis (NASDAQ:ENTL) : December 13, 2016 (NASDAQ:ENTL)
www.capitalcube.com - December 13 at 11:31 AM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : December 12, 2016 (NASDAQ:ENTL)
www.capitalcube.com - December 12 at 11:52 AM
us.rd.yahoo.com logoCoverage initiated on Entellus Medical by Guggenheim (NASDAQ:ENTL)
us.rd.yahoo.com - December 8 at 1:37 AM
finance.yahoo.com logoEntellus Medical Announces Publication of Positive Clinical Data for XprESS for Treatment of Pediatric Chronic Rhinosinusitis (NASDAQ:ENTL)
finance.yahoo.com - November 29 at 5:31 PM
finance.yahoo.com logo8:53 am Entellus Medical announces results of a prospective, multicenter clinical study using its XprESS balloon sinus dilation system in pediatric patients were published in the peer reviewed journal International Forum of Allergy & Rhinol (NASDAQ:ENTL)
finance.yahoo.com - November 29 at 5:31 PM
finance.yahoo.com logoEdited Transcript of ENTL earnings conference call or presentation 3-Nov-16 8:30pm GMT (NASDAQ:ENTL)
finance.yahoo.com - November 22 at 4:34 PM
finance.yahoo.com logoEntellus Medical to Present at the Piper Jaffray Healthcare Conference (NASDAQ:ENTL)
finance.yahoo.com - November 16 at 4:58 PM
capitalcube.com logoETF’s with exposure to Entellus Medical, Inc. : November 8, 2016 (NASDAQ:ENTL)
www.capitalcube.com - November 8 at 3:56 PM
capitalcube.com logoEntellus Medical, Inc. :ENTL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 (NASDAQ:ENTL)
www.capitalcube.com - November 7 at 4:48 PM
einnews.com logoEntellus Medical Announces Third Quarter 2016 Financial Results (NASDAQ:ENTL)
world.einnews.com - November 4 at 9:36 AM
sg.finance.yahoo.com logoEntellus reports 3Q loss (NASDAQ:ENTL)
sg.finance.yahoo.com - November 3 at 10:27 PM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : November 1, 2016 (NASDAQ:ENTL)
www.capitalcube.com - November 1 at 9:09 AM
publicnow.com logoEntellus Medical to Report Third Quarter 2016 Financial Results on November 3, 2016 (NASDAQ:ENTL)
www.publicnow.com - October 24 at 4:43 PM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bullish Manner : ENTL-US : October 17, 2016 (NASDAQ:ENTL)
www.capitalcube.com - October 17 at 9:50 AM
finance.yahoo.com logoCoverage initiated on Entellus Medical by Deutsche Bank (NASDAQ:ENTL)
finance.yahoo.com - October 6 at 4:48 PM
capitalcube.com logoETF’s with exposure to Entellus Medical, Inc. : October 6, 2016 (NASDAQ:ENTL)
www.capitalcube.com - October 6 at 10:28 AM
capitalcube.com logoETF’s with exposure to Entellus Medical, Inc. : September 9, 2016 (NASDAQ:ENTL)
www.capitalcube.com - September 9 at 4:41 PM
capitalcube.com logoEntellus Medical, Inc. :ENTL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:ENTL)
www.capitalcube.com - August 11 at 4:59 PM
capitalcube.com logoETF’s with exposure to Entellus Medical, Inc. : August 10, 2016 (NASDAQ:ENTL)
www.capitalcube.com - August 10 at 5:03 PM
capitalcube.com logoEntellus Medical, Inc. breached its 50 day moving average in a Bearish Manner : ENTL-US : August 9, 2016 (NASDAQ:ENTL)
www.capitalcube.com - August 9 at 3:32 PM

Social

What is Entellus Medical's stock symbol?

Entellus Medical trades on the NASDAQ under the ticker symbol "ENTL."

Where is Entellus Medical's stock going? Where will Entellus Medical's stock price be in 2017?

6 brokers have issued twelve-month target prices for Entellus Medical's stock. Their forecasts range from $16.00 to $26.00. On average, they expect Entellus Medical's stock price to reach $22.80 in the next twelve months.

When will Entellus Medical announce their earnings?

Entellus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.

What are analysts saying about Entellus Medical stock?

Here are some recent quotes from research analysts about Entellus Medical stock:

  • According to Zacks Investment Research, "Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. " (1/31/2017)

  • Canaccord Genuity analysts commented, "We maintain our BUY rating following marketing meetings with management. We recently hosted Entellus Medical’s management team for a day of investor meetings in Boston. We traveled with Bob White, President and CEO and Brent Moen, CFO. Meetings were largely positive as procedural growth (both office based and OR) and reimbursement changes remain a focus for investors. We came away from those meetings with a clearer understanding of reimbursement changes, broader product portfolio, and OUS growth potential. Net, net we remain positive about Entellus’ growth opportunities despite investor uncertainty on the reimbursement front headed into 2017. Near term, as management noted on the Q3/16 conference call, we expect Entellus will set conservative guidance for 2017 to the low end of the historic 20%-25% range, and as such, set the potential for a beat and raise cadence over the H2/17. We expect reimbursement will be at the forefront of investor minds moving into 2017 as the industry digests 30-50% cuts to reimbursement in the hospital outpatient setting." (12/20/2016)

Who owns Entellus Medical stock?

Entellus Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include SV Life Sciences Advisers LLC (18.50%), Discovery Group I LLC (3.95%), FMR LLC (3.74%), First Light Asset Management LLC (2.07%), Cortina Asset Management LLC (1.78%) and Arrowpoint Asset Management LLC (1.66%). Company insiders that own Entellus Medical stock include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick.

Who sold Entellus Medical stock? Who is selling Entellus Medical stock?

Entellus Medical's stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC. Company insiders that have sold Entellus Medical stock in the last year include Brian E Farley, James D Surek, Karen E Peterson, Kevin L Mensink, Life Sciences Fu International, Margaret A Boiano and Timothy B Petrick.

Who bought Entellus Medical stock? Who is buying Entellus Medical stock?

Entellus Medical's stock was bought by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, Millrace Asset Group Inc., Discovery Group I LLC, Royce & Associates LP, William Blair Investment Management LLC, Kingdon Capital Management L.L.C., Renaissance Technologies LLC and Quinn Opportunity Partners LLC.

How do I buy Entellus Medical stock?

Shares of Entellus Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Entellus Medical stock cost?

One share of Entellus Medical stock can currently be purchased for approximately $13.92.

Entellus Medical (NASDAQ:ENTL) Chart for Wednesday, March, 1, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Earnings History Chart

Earnings by Quarter for Entellus Medical (NASDAQ:ENTL)

Dividend History Chart

Dividend Payments by Quarter for Entellus Medical (NASDAQ:ENTL)

Last Updated on 3/1/2017 by MarketBeat.com Staff